PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2852251
NIHMSID: NIHMS182002

Disabled-2 is a FOXP3 target gene required for regulatory T cell function

Abstract

FOXP3 expressing regulatory T cells are vital for maintaining peripheral T cell tolerance and homeostasis. The mechanisms by which FOXP3 target genes orchestrate context-dependent Treg cell function are largely unknown. Here we show that in mouse peripheral lymphocytes, the Drosophila Disabled-2 (Dab2) homolog, a gene that is involved in enhancing TGFβ responses, is exclusively expressed in FOXP3+ regulatory T cells. Dab2 is a direct target of FOXP3 and regulatory T cells lacking DAB2 are functionally impaired in vitro and in vivo. However, not all aspects of Treg cell function are perturbed and DAB2 appears dispensable for Treg cell function in maintaining naïve T cell homeostasis.

Introduction

FOXP3 expressing regulatory T (Treg) cells are a subset of suppressor CD4+ T cells that are necessary for controlling peripheral T cell tolerance (1). Null mutations in the Foxp3 gene in humans and mice leads to fatal, early onset autoimmunity (2). Treg cell mediated suppression in vivo is postulated to be highly context-dependent and likely involves failsafe, multiple effector components. The absolute requirement for FOXP3 in Treg cell function has stimulated intensive investigations to identify FOXP3 target genes and proteins. Phosphodiesterase 3b (Pde3b), which controls cAMP availability (3), Ctla4, which likely regulates APC function (46), Ebi3, which encodes for the IL-27β chain of regulatory cytokine, IL-35 (7), and microRNA mir155 that maintains IL-2 responsiveness of Treg cells (8) are direct gene targets of FOXP3 that have been shown to be variably required for Treg cell function and homeostasis.

Here, we show that Dab2 is a target gene of FOXP3 that is critical for Treg cell function in vitro and in vivo. Unlike previously identified targets of FOXP3, Dab2 expression is restricted to CD4+ Treg cells in peripheral lymphocyte subsets. In non-lymphoid cells, DAB2 has several critical functions in cell development and transformation by enhancing SMAD activation during TGFβ signaling (9, 10), in GAP junction functions (11), and in clathrin coated pit-mediated endocytosis of cell surface receptors (12). Dab2 expression is also regulated by the Vitamin A metabolite all-trans Retinoic Acid (ATRA) (13). Considering the role of TGFβ and ATRA in regulating FOXP3 expression in Treg cells as well as their function (14, 15), we hypothesized that DAB2 is required for Treg cell function.

Analyses of mice with a T cell-restricted Dab2-deficiency showed that they generate normal numbers of Treg cells, but these Treg cells are not functional in vitro. While Dab2-deficient mice appear healthy and do not show significant perturbations in maintenance of peripheral naive T cell homeostasis, Dab2-deficient Treg cells are impaired in controlling colitogenic T cells in an adoptive transfer model.

Materials and Method

Mice

Dab2fl/fl (B6×129) mice (16) were backcrossed 4 times onto B6 background. T cell specific deletion of Dab2 was obtained by crossing Dab2fl/fl mice with either Cd2CreTg+ or Cd4CreTg+ mice (17). Foxp3eGFP reporter mice (18) were a kind gift from V. Kuchroo (Harvard medical School). Rag1–/– and C57Bl/6 mice were obtained from Jackson Laboratories. All experiments were approved by the Umass Institutional Animal Care and Use Committee.

Antibodies, Flow cytometry and cell sorting

Cells were stained for surface markers (Abs from BD Bioscience and eBioscience) followed by FOXP3 staining according to eBioscience instructions. cAMP antibody was from Abcam. Samples were acquired on a Becton Dickinson LSRII flow cytometer and data analyzed using FlowJo software (Treestar). Thymic and peripheral T cell subsets were sorted to greater than 95% purity using using a MoFlo cell sorter (Dako).

Retroviral Infection

NFC (αβ, CD4+CD8+) thymoma cells were infected with a control MSCV retroviral vector containing GFP or with an MSCV retroviral vector carrying the full-length Foxp3cDNA cloned upstream of an IRES and GFP. Stable cell lines that express vector alone (V) and MSCV-Foxp3 (F) were generated by cell sorting and maintained in complete DMEM (10% FBS, 50µM 2-mercaptoethanol, 2mM L-glutamine, 20mM Hepes, 0.1mM non-essential amino acids).

RT-PCR and real-time PCR

RNA was isolated from cells with Trizol Reagent (Invitrogen) and cDNA was prepared using an Omniscript RT-PCR kit (Qiagen). For semi-quantitative RT-PCR (sqRT-PCR), 3-fold serial dilutions of cDNA were used. PCR primers are listed in Supplemental Data 1. Real-time PCR amplification was performed using iQ SYBR Green supermix (BioRad). All data were normalized to Actb mRNA expression and represented as arbitrary units (AU).

Chromatin Immunoprecipitation (ChIP) Assays

FOXP3 over-expressing NFC cells (F) and vector control cells (V) were stimulated with PMA (50ngml) and ionomycin (100ng/ml) at 37°C for 24 hours. ChIP assays were performed on 1×106 cells using the ChIP Assay Kit (Upstate Cell signaling Solutions). Immuno-precipitation was performed using anti-FOXP3 antibody (Santa Cruz). The recovered DNA was dissolved in 20 µl of H2O and analyzed by PCR. PCR primers used are listed in Supplemental Figure 1.

In vitro FOXP3 induction

Sorted CD4+FOXP3 T cells from Foxp3eGFP reporter mice were activated with plate-bound anti-CD3 (0.5µg/ml; clone 500A2) and anti-CD28 (1.0µg/ml; clone 37N) in the presence of rTGFb (2ng/ml; R&D) and all-trans retinoic acid (ATRA) (100nM; Sigma).

In vitro suppression assay

Sorted CD4+CD25+ were activated in vitro as described above, in the presence of 100U/ml of rIL-2 in complete DMEM for 48 hours. Post-stimulation, indicated numbers of Treg cells were co-cultured with 5×104 freshly isolated CD4+T cells and 5×104 irradiated splenocytes from B6 mice and activated with plate-bound anti-CD3 for 72 hours. [3H]TdR incorporation was measured over the last 6 hours.

Colitis induction and cure

4×105 naïve CD4+CD25 cells from wt mice and, 2×105 sorted CD4+CD25+ regulatory T cells were co-injected into lymphocyte-deficient (Rag1–/–) mice. For colitis “rescue” experiments, 4x105 naïve CD4+CD25CD45RBhi T cells were injected into Rag1–/– mice to induce colitis. 4 weeks later, 1x106 CD4+CD25+ regulatory T cells were injected. Colonic pathology was determined at 2–3 weeks after transfer of Treg cells by standard H&E staining of formalin fixed tissues. Colitis was scored as described in (19).

Calcein AM intercellular transfer, cAMP ELISA

Sorted CD4+CD25+ Treg cells were loaded with calcein as described in (20) and co-cultured with Ly5.1+CD4+T cells. Cells were activated as described above and calcein transfer was detected by flow cytometry after 16 hours. To measure intracellular cAMP amounts, sorted CD4+CD25+ and CD4+CD25 cells were washed in ice-cold PBS and lysed in 0.1NHCl and a cAMP specific ELISA was performed according to the manufacturer’s protocol (BioMol and Promega).

Results and Discussion

Dab2 expression is restricted to FOXP3+ Treg cells

We infected NFC αβTCR+ CD4+CD8+ cells with a retrovirus vector containing Foxp3 cDNA, followed by global gene expression profiling to determine genes whose expression was changed by the ectopic Foxp3 expression (data not shown). One of only a few genes that were altered in expression was Dab2 (Drosophila Disabled homolog-2), as illustrated by a confirmatory RT-PCR assay (Fig. 1A). In peripheral T cell subsets, Dab2 expression was restricted exclusively to CD4+FOXP3+ Treg cells (Fig. 1B). In the thymus, Dab2 was expressed in early precursor cells (data not shown) and in mature FOXP3+ CD4SP (CD4+CD8) cells (Fig. 1C). Dab2 was also expressed in TGFβ-induced FOXP3+ Treg cells in vitro and its expression was enhanced by ATRA (Fig. 1D), an inducer of Dab2 expression in non-lymphoid cells.

Figure 1
FOXP3 dependent Dab2 expression in regulatory T cells

To determine whether FOXP3 can bind to the Dab2 regulatory region, we performed ChIP analysis by selecting relevant FOXP3 consensus binding sites in the regulatory sequences of Dab2 based on conservation between the mouse and human Dab2 genomic loci. Among four such conserved consensus binding sites tested, only one located in the 5’ untranslated region, ~2.3 kb upstream of the transcriptional site of the Dab2 gene, was found to be associated with FOXP3 in FOXP3+ NFC cells (Fig. 1E). These results identify Dab2 as a potential direct target gene of FOXP3.

Dab2 deficiency alters Treg cell function

To determine the function of DAB2 in Treg cells, we generated mice lacking Dab2 specifically in T cells. We analyzed both Cd2 promoter-Cre Tg+×Dab2fl/fl and Cd4 promoter-Cre Tg+×Dab2fl/fl mice that delete the floxed Dab2 gene during early (CD3 CD4CD8 TN) and late (CD4+CD8+ DP) stages of intrathymic T cell development, respectively. Treg cells in conditional Dab2-knockout (CKO) mouse lines lacked Dab2 expression (Fig. 1B). As Treg cells in both models were indistinguishable in function and phenotype we present data predominantly from the analysis of Dab2fl/fl:Cd4 mice, herewith referred to as Dab2 CKO mice.

Mice lacking DAB2 in Treg cells were healthy in appearance and did not suffer from overt autoimmunity even at 10–12 months of age, suggesting that the mutant Treg cells were capable of maintaining naïve T cell tolerance. The frequency of thymic and peripheral CD4+FOXP3+ cells was unchanged in Dab2 CKO mice compared to wt mice. The Treg cells were also phenotypically similar to wt Treg cells and expressed normal levels of CTLA-4, GITR and IL-7R (Supplemental Figure 2).

We first tested the functionality of Dab2 CKO Treg cells in an in vitro suppression assay. Whereas wt Treg cells suppressed the proliferation of responder T cells in a Treg cell number-dependent manner, Treg cells from Dab2 CKO mice were unable to do so (Fig 2C). Next, we determined the ability of purified Treg cells from Dab2 CKO mice to control co-injected pathogenic naïve (CD4+CD25) T cells when transferred into lymphopenic animals. In contrast to the complete lack of function of Dab2-deficient Treg cells in vitro, they were as effective as wt Treg cells in preventing the induction of colitis by naïve T cells transferred into Rag1–/– mice (Fig. 2D). However, in a more stringent model of Treg cell function, Dab2-deficient Treg cells failed to moderate established colitis (21) (Fig. 2E). While wt Treg cells effectively cured colitis, Dab2 CKO Treg cells were defective in regulating on-going, aggressive lymphocyte infiltration and accumulation in the colon that led to a progressive wasting disease (Fig. 2F).

Figure 2
Dab2 deficient Treg cells are functionally impaired

Impaired Gap-junction function by Dab2-deficient Treg cells

We next investigated the mechanistic basis for the observed defects in Dab2-deficient Treg cells by examining potential molecules and/or pathways involved in Treg cell-mediated immune suppression. Treg cells from Dab2-deficient mice produced normal amounts of IL-10, expressed comparable amounts of Il10, TGFβ and Ebi3 at the transcriptional level and expressed normal amounts of Granzyme B (data not shown). One mechanism by which Treg cells suppress target cell proliferation and activation is by transferring cAMP through GAP junctions to effector T cells (20). Since DAB2 is known to interact with connexins that make up the GAP junctions (11), we tested whether Dab2-deficient Treg cells were poor suppressors in vitro because they had deficiencies in GAP junction-mediated intercellular communication (GJIC). We labeled Treg cells from wt and Dab2 CKO mice with a GAP junction transferable dye, Calcein AM, and co-cultured these with congenically marked wt responder cells. Dab2-deficient Treg cells were unable to transfer the dye as efficiently as wt Treg cells (Fig. 3A). In addition, Dab2-deficient Treg cells expressed higher amounts of intracellular cAMP compared to wt Treg cells (Fig. 3B,C). These results suggest that one impaired function in Dab2-deficient Treg cells involves the GJIC, while other mechanisms of Treg cell-mediated suppression examined appeared largely intact.

Figure 3
Dab2 deficient Treg cells have impaired Gap-junction function

Collectively, we have identified Dab2 as a FOXP3 target gene that is required for a subset of Treg cell function. Dab2 expression is higher in CD44+ Treg cells compared to CD44 Treg cells (data not shown) and whether all FOXP3+ Treg cells express Dab2 is currently under investigation. Although Dab2 is expressed only in Treg cells among peripheral lymphocytes, it is also expressed specifically in TN3 thymocytes and is required for normal TGFβ and/or Activin responses of lymphocytes (Jain et al., manuscript in preparation).

Given the FOXP3-dependent expression of Dab2 in mature Treg cells and the established function of DAB2 in promoting TGFβ signaling (9), one possibility was that Dab2 CKO mice would phenocopy the loss of Treg cells observed in mice with defective TGFβ signaling (22). However, Dab2 CKO mice maintained normal numbers of Treg cells, suggesting that DAB2 may be required for amplification, rather than maintenance, of TGFβ signaling in as yet undefined context. Dab2-deficient Treg cells do not function in vitro and cannot cure established colitis in vivo, but they retain sufficient suppressive activity to maintain T cell homeostasis in unperturbed mice. This selective Treg cell defect is another indication that Treg cells employ multiple, context-dependent modes of immunosuppression. Although the reduced GAP junction activities appear to be the only distinguishing feature of Dab2-deficient Treg cells that has previously been correlated with impaired in vitro suppression, whether this is the cause of impaired function of Dab2-deficient Treg cells remains to be established. The in vivo context in which DAB2 is essential for Treg cell function is an outstanding issue that will require further studies.

Supplementary Material

01

Acknowledgements

We thank the UMass Flow Facility for cell sorting, and Drs. Leslie Berg and Raymond Welsh for helpful discussions and Dr. Werner Held and Kavitha Narayan for critical reading of the manuscript.

This project was supported by grants from NIH to C.A.C. and J.K.(AI054670, AI59880.

Abbreviations used in this paper

Treg
T regulatory
ATRA
all-trans retinoic acid
CKO
conditional knock-out

Footnotes

Disclosures

The authors have no financial conflict of interest.

Contributor Information

N Jain, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

H Nguyen, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

RH Friedline, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

N Malhotra, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

M Brehm, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

M Koyonagi, Department of Immunology, St. Jude Children’s Research Hospital, 332 N Lauderdale St., Memphis, TN 38105.

M Bix, Department of Immunology, St. Jude Children’s Research Hospital, 332 N Lauderdale St., Memphis, TN 38105.

JA Cooper, Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.

CA Chambers, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

J Kang, Department of Pathology, Graduate Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N., Worcester, MA 01655.

References

1. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, N.Y. 2003;299:1057–1061. [PubMed]
2. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21. [PubMed]
3. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–775. [PubMed]
4. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science (New York, N.Y. 2008;322:271–275. [PubMed]
5. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. The Journal of experimental medicine. 2009;206:421–434. [PMC free article] [PubMed]
6. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126:375–387. [PubMed]
7. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569. [PubMed]
8. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY. Foxp3- dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30:80–91. [PMC free article] [PubMed]
9. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. Embo J. 2001;20:2789–2801. [PubMed]
10. Prunier C, Howe PH. Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT) J Biol Chem. 2005;280:17540–17548. [PubMed]
11. Piehl M, Lehmann C, Gumpert A, Denizot JP, Segretain D, Falk MM. Internalization of large double-membrane intercellular vesicles by a clathrin-dependent endocytic process. Mol Biol Cell. 2007;18:337–347. [PMC free article] [PubMed]
12. Morris SM, Cooper JA. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic. 2001;2:111–123. [PubMed]
13. Cho SY, Cho SY, Lee SH, Park SS. Differential expression of mouse Disabled 2 gene in retinoic acid-treated F9 embryonal carcinoma cells and early mouse embryos. Mol Cells. 1999;9:179–184. [PubMed]
14. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. The Journal of experimental medicine. 2003;198:1875–1886. [PMC free article] [PubMed]
15. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (New York, N.Y. 2007;317:256–260. [PubMed]
16. Morris SM, Tallquist MD, Rock CO, Cooper JA. Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. Embo J. 2002;21:1555–1564. [PubMed]
17. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Perez-Melgosa M, Sweetser MT, Schlissel MS, Nguyen S, Cherry SR, Tsai JH, Tucker SM, Weaver WM, Kelso A, Jaenisch R, Wilson CB. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity. 2001;15:763–774. [PubMed]
18. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238. [PubMed]
19. Asseman C, Read S, Powrie F. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J Immunol. 2003;171:971–978. [PubMed]
20. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. The Journal of experimental medicine. 2007;204:1303–1310. [PMC free article] [PubMed]
21. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunological reviews. 2006;212:256–271. [PubMed]
22. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nature reviews. 2007;7:443–453. [PubMed]
23. Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27:786–800. [PubMed]